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Abstract
 
Cellular interleukin 10s (cIL-10s) of human and murine origin have extensive sequence and
structural homology to the Epstein-Barr virus 
 
BCRF-I 
 
gene product, known as viral IL-10
(vIL-10). Although these cytokines share many immunosuppressive properties, vIL-10 lacks
several of the immunostimulatory activities of cIL-10 on certain cell types. The molecular and
cellular bases for this dichotomy are not currently defined. Here, we show that the single
amino acid isoleucine at position 87 of cIL-10 is required for its immunostimulatory function.
Substitution of isoleucine in cIL-10 with alanine, which corresponds to the vIL-10 residue, ab-
rogates immunostimulatory activity for thymocytes, mast cells, and alloantigenic responses
while preserving immunosuppressive activity for inhibition of interferon 
 
g
 
 production and
prolongation of cardiac allograft survival. Conversely, substitution of alanine with isoleucine in
vIL-10 converts it to a cIL-10–like molecule with immunostimulatory activity. This single con-
servative residue alteration significantly affects ligand affinity for receptor; however, affinity
changes do not necessarily alter specific activities for biologic responses in a predictable fashion.
These results suggest complex regulation of IL-10 receptor–ligand interactions and subsequent
biological responses. These results demonstrate that vIL-10 may represent a captured and selec-
tively mutated cIL-10 gene that benefits viral pathogenesis by leading to ineffective host im-
mune responses. The ability to manipulate the activity of IL-10 in either a stimulatory or sup-
pressive direction may be of practical value for regulating immune responses for disease
therapy, and of theoretical value for determining what aspects of IL-10 activity are important
for normal T cell responses.
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Introduction
 
IL-10 was originally described as cytokine synthesis inhibi-
tory factor because of its ability to turn off cytokine pro-
duction by T cells (1). Further investigations demonstrated
that the immunosuppressive effects of IL-10 are often at the
level of the APC as well as at the level of the T cell (2).
Thus, IL-10 inhibits monocyte and macrophage synthesis
of IL-1
 
a
 
, IL-1
 
b
 
, IL-6, IL-8, IL-12, TNF-
 
a
 
, GM-CSF, and
reactive oxygen and nitrogen intermediates (3–6). IL-10
can effectively treat the cytokine syndrome and toxicity
caused by anti-CD3 mAb or endotoxin by inhibiting the
production of proinflammatory cytokines (7–9). Autoim-
mune models of rheumatoid arthritis, thyroiditis, and col-
lagen-induced arthritis and a model of herpetic stromal
keratitis all suggest negative regulatory roles for IL-10 in
limiting inflammation and immunopathology (10–13). IL-
10–deficient knockout mice have highly polarized Th1 re-
sponses and develop a severe colitis related to chronic stim-
ulation by enteric antigens (14). In humans, Crohn’s colitis
may even be susceptible to treatment with systematically
administered IL-10 (15). Further reinforcement for the no-
tion that IL-10 is an immunosuppressive cytokine came
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from the discovery of viral IL-10 (vIL-10)
 
1
 
 (16), which was
shown to have identical immunosuppressive properties to
cellular IL-10 (cIL-10), inhibiting IFN-
 
g
 
 production, MHC
class II expression, T cell proliferation, and B cell IgE pro-
duction (17–22).
However, cIL-10 also has immunostimulatory properties
in some circumstances. It can act as a stimulatory factor for
immature and mature thymocytes, mast cells, and B cells
(23–25). Interestingly, although cIL-10 can costimulate thy-
mocyte and mast cell proliferation and B cell MHC class II
expression, vIL-10 cannot (18, 22, 23), suggesting differ-
ences in the structure and function of the two molecules.
Transduction of tumors with a retroviral vector encoding
mouse (m)IL-10 results in enhanced antitumor immunity
and rejection, whereas vIL-10 tumor cell transduction re-
sults in immune suppression and tumor growth (26). Our
previous studies showed that rejection of mouse heart al-
lografts was substantially inhibited when the grafts were in-
duced by retroviral gene transfer to express vIL-10, but not
mIL-10 (27). These observations suggest that vIL-10 has
preserved only a subset of the activities of cIL-10 and imply
the existence of at least two functional domains, stimula-
tory and suppressive, only the latter of which has been con-
served by EBV. The structural basis for the two activities
within cIL-10, or between cIL-10 and vIL-10, has not
been elucidated. Using structure–function analysis, we now
report that the single amino acid isoleucine at position 87
of cIL-10 is critical for immunostimulatory activity. The
finding that a single amino acid can determine the range of
immunological properties of IL-10 provides a structural
lead for defining the separate functions of IL-10 and should
facilitate the dissection of the cellular and molecular events
that are regulated by the IL-10 molecule. Moreover, it may
provide a basis for the design of novel IL-10–related thera-
peutic reagents for clinical application.
 
Materials and Methods
 
Chimeric IL-10 Constructs and Transfection.
 
mIL-10 and vIL-10
were cloned into the pMP6A expression vector, which has a
CMVie promoter (28; Applied Immune Sciences, Inc.). A series
of chimeric mIL-10/vIL-10 cDNAs was constructed and cloned by
PCR-based site-directed mutagenesis (29). The 5
 
9
 
 external primer
containing a HindIII site, and 3
 
9
 
 external primer containing a
BamHI site were synthesized and used to amplify the relevant re-
gion. The internal primers at the specific sites of mIL-10 or vIL-10
joining were synthesized and phosphorylated, mIL-10 PCR frag-
ments were ligated to vIL-10 PCR fragments, the ligation products
were digested with HindIII and BamHI, and the final product was
ligated to pMP6A. For point mutations, internal primers contain-
ing specific mutations were used for PCR. Some human IL-10
(hIL-10) constructs were cloned into the pcDNA3.1myc-his vec-
 
tor (Invitrogen). All constructs were sequenced to confirm fidel-
ity. Purified chimeric cDNA plasmids were transfected into
COS-7 cells by calcium phosphate method, and the COS cell su-
pernatants were harvested after 48 h. Protein expression was ana-
lyzed by internal [
 
35
 
S]methionine labeling (16). In brief, cell cul-
tures on the second day after transient transfection were cultured
in 3 ml of methionine-deficient medium supplemented with
[
 
35
 
S]methionine (Amersham Pharmacia Biotech) at 100 
 
m
 
Ci/ml
and tunicamycin at 170 ng/ml for 48 h. Supernatants were con-
centrated 10-fold and analyzed by 14% SDS-PAGE. For Western
blotting, COS cell supernatants of COOH-terminal myc-his–
tagged hIL-10 were concentrated fivefold, run on an 8–16%
SDS-PAGE gel, transferred to a nitrocellulose membrane, blotted
with anti-myc mAb (1:10,000; Invitrogen), and developed se-
quentially with anti–mouse IgG-horseradish peroxidase (1:7,500;
Amersham Pharmacia Biotech) and enhanced chemiluminescent
reagents (Amersham Pharmacia Biotech).
 
Cell Culture, Proliferation Assays, and IFN-
 
g
 
 Inhibition.
 
1 
 
3 
 
10
 
5
 
thymocytes from CBA/J mice were incubated in complete
RPMI medium (RPMI 1640 supplemented with 10% FCS, 1 mM
sodium pyruvate, 2 mM 
 
l
 
-glutamine, 100 IU/ml penicillin, 100
 
m
 
g/ml streptomycin, 1
 
3
 
 nonessential amino acids, and 2 
 
3 
 
10
 
2
 
5
 
M 2-ME) with mIL-2 (500 U/ml; PharMingen), mIL-4 (250 U/ml;
PharMingen), and various amounts (1–20%) of COS cell super-
natants for 3–5 d (22). Proliferation was assessed by 18-h [
 
3
 
H]thy-
midine incorporation. The MC/9 cell line was purchased from
American Type Culture Collection and grown in RPMI plus
10% FCS and 5% mouse ConA supernatants. MC/9 cells were
rested in complete media overnight, then 1 
 
3 
 
10
 
5
 
 cells per well
were incubated with various concentrations of IL-10 COS super-
natants for 24 h, and proliferation was assessed by 6-h [
 
3
 
H]thymi-
dine incorporation (24). Ba/F3 cells expressing recombinant
mIL-10R1 were a gift from Dr. K. Moore (DNAX, Inc., Palo
Alto, CA) and maintained as described (29). Proliferation of Ba/
F3-mIL-10R1 transfectants in response to IL-10 was analyzed as
described (30, 31) with a colorimetric assay using Alamar blue
(Accurate Chemical). For inhibition of IFN-
 
g
 
 production, PBMCs
were purified from healthy donors using Ficoll-Paque Plus (Am-
ersham Pharmacia Biotech), 2 
 
3 
 
10
 
5
 
 cells per well were incu-
bated with soluble OKT3 (0.1 
 
m
 
g/ml) plus various concentra-
tions of IL-10 COS supernatants for 48 h, and IFN-
 
g
 
 production
was measured by two-antibody capture ELISA (PharMingen) and
compared with an IFN-
 
g
 
 standard (PharMingen). The concen-
tration of various IL-10s that induced half-maximal responses in
each of the bioassays was defined as 1 U/ml and used to compare
specific activities of the various constructs and the different assays.
 
Cardiac Transplantation.
 
Donor neonatal C57BL/6 mice were
killed, and whole hearts were removed, injected with 0.31 
 
m
 
g of
various IL-10 plasmid DNA constructs complexed with 10 
 
m
 
g of
dendrimer G5-EDA to enhance transfection (32), and trans-
planted into CBA/J recipients. Survival of cardiac allografts was
followed with EKG monitoring every other day. Cessation of
cardiac electrical activity was the determinant of rejection. 
 
P
 
 val-
ues were calculated by Student’s 
 
t
 
 test.
 
Induction of HLA-B7 and Electrophoretic Mobility Shift Assay of
Signal Transducers and Activators of Transcription.
 
The 16-9 Chi-
nese hamster ovary (CHO) cells transfected with an HLA-B7 re-
porter construct and expressing hIL-10R1/hIFN-
 
g
 
R1 chimera,
hIL-10R2, or hIL-10R1/hIFN-
 
g
 
R1 plus hIL-10R2 (33) were
maintained in complete F12 medium containing 450 
 
m
 
g/ml
G418. 1 
 
3
 
 10
 
5
 
 cells were treated with 10% COS supernatants of
hIL-10 or hIL-10(I87A) for 72 h. HLA-B7 antigen was detected
by treatment of cells with anti-HLA (w6/32) mAb, followed by
 
1
 
Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; cIL-10,
cellular IL-10; EMSA, electrophoretic mobility shift assay; h, human;
hIL-10(I87A), the isoleucine to alanine substitution at position 87 of hIL-
10; JAK, Janus kinase; m, mouse; STAT, signal transducer and activator
of transcription; vIL-10, viral IL-10; vIL-10(A87I), the alanine to isoleu-
cine substitution at position 87 of vIL-10. 
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treatment with FITC-conjugated goat anti–mouse IgG (Phar-
Mingen), and 1 
 
3
 
 10
 
4
 
 cells were analyzed by FACScan™ (Becton
Dickson). For electrophoretic mobility shift assay (EMSA), 2 
 
3
 
10
 
6
 
 cells were exposed to 4 ml 100% COS cell supernatants con-
taining hIL-10 or hIL-10(I87A) for 15 min. The cells were lysed,
and nuclear extracts were obtained for binding to 
 
32
 
P-labeled 22-
bp IFN-
 
g
 
 activation sequence (GAS) element in the promoter re-
gion of the human IFN regulatory factor 1 (IRF-1) gene (33). 1 
 
m
 
l
of anti–signal transducer and activator of transcription 1 (Stat1) or
anti-Stat3 antibodies (Santa Cruz Biotechnology) was added to
the incubation mixture, incubated for 20 min at 22
 
8
 
C, then 4 
 
m
 
l
of the reaction mixture was electrophoresed at 200 V for 4 h at
4
 
8
 
C on a 16 
 
3 
 
16 cm 5% polyacrylamide (19:1 acrylamide/
bisacrylamide) gel. The dried gel was exposed to Kodak XAR-5
film with an intensifying screen for 2 d at 
 
2
 
80
 
8
 
C. When IL-3–
dependent derivatives of the Ba/F3-mIL-10R1 cell line were
used, 5 
 
3
 
 10
 
6 
 
cells were plated in the absence of IL-3, cultured
for 4 h, and then stimulated with 4 ml 100% COS cell superna-
tants containing hIL-10 or hIL-10(I87A) for 15 min. Nuclear ex-
tracts and EMSAs were performed as described previously by us-
ing the 
 
32
 
P-labeled 18-bp probe based on the IFN-
 
g
 
 response
region (GRR) within the promoter of the Fc
 
g
 
RI gene (34).
 
Protein Purification.
 
hIL-10, hIL-10(I87A), vIL-10, and vIL-
10(A87I) were purified by the pMAL Protein Fusion and Purifi-
cation System (New England Biolabs). PCR fragments were cre-
ated encoding the mature proteins with EcoRI and BamHI sites
at the 5
 
9
 
 and 3
 
9
 
 ends, respectively. The EcoRI-BamHI restriction
fragments encoding hIL-10 and hIL-10(I87A) were cloned into
pMAL-c2 vector, which leads to cytoplasmic expression of the
maltose binding protein (MBP) fusion proteins in 
 
Escherichia coli
 
,
and the EcoRI-BamHI restriction fragments encoding vIL-10 and
vIL-10(A87I) were cloned into pMAL-p2 vector, which leads to
periplasmic expression of similar constructs. Fusion proteins were
isolated from bacterial cell lysates and purified by maltose affinity
column, cleaved by factor Xa, and repurified by Q-Sepharose ion
exchange chromatography according to the manufacturer’s rec-
ommendations. Purified proteins were run on an 8–16% SDS-
PAGE gel, analyzed by silver staining, and purity 
 
.
 
95% was
achieved in all cases. Purified protein concentrations were deter-
mined by measuring absorbance at 280 nm by comparison with a
calibration curve prepared from measurements with standard
hIL-10 (PeproTech) solutions. Endotoxin was 
 
,
 
0.1 ng/
 
m
 
g as
determined by Endotoxin kit (Sigma Chemical Co.).
 
125
 
I-labeled hIL-10 Competitive Displacement.
 
125
 
I-labeled hIL-
10 (75–140 
 
m
 
Ci/
 
m
 
g) was purchased from NEN Life Science
Products. 
 
125
 
I-labeled hIL-10 binding and competitive displace-
ment were assessed as described (31). In brief, 5 
 
3
 
 10
 
5
 
 Ba/F3-
mIL-10R1 cells were incubated in 200 
 
m
 
l as duplicate samples in
100 pM 
 
125
 
I-labeled hIL-10 in the presence of between 0.6 pM
and 200 nM hIL-10, hIL-10(I87A), vIL-10, and vIL-10(A87I)
for 4 h at 4
 
8
 
C in RPMI 1640, 2% BSA, 0.02% sodium azide
(binding buffer) with shaking. Reaction mixtures were overlaid
onto 150 
 
m
 
l of dibutyl phthalate/dioctyl phthalate (3:2) in conical
bottom tubes and centrifuged for 1 min (Eppendorf 5413). The
pellets were cut off with a razor blade and analyzed in a CO-
BRA
 
®
 
 II gamma counter (Packard Instruments).
 
Results
 
Isoleucine 87 of cIL-10 Is Critical for Proliferative Activity.
 
hIL-10 has 84% amino acid identity to viral IL-10 and 73%
identity to mIL-10. The linear structure of IL-10 (Fig. 1 a)
 
and crystallographic data show that the greatest differences
among vIL-10 and cIL-10s lie in the NH
 
2
 
 terminus, imply-
ing that these differences in structure may ultimately lead to
changes in immunological function (35–38). To map which
region(s) of the IL-10 molecule determines the immuno-
stimulatory and immunosuppressive activities of the cyto-
kine, we constructed a series of chimeric hybrids that recip-
rocally exchanged the NH
 
2
 
 or COOH one third of the
molecules between mIL-10 and vIL-10 (Fig. 1 b). Because
of close molecular homology, it was likely that such ex-
changes would not destroy overall structure and biological
activity, but selectively choose for restricted biological
function. Plasmid expression vectors containing these fu-
sion constructs were transfected into COS-7 cells, and the
cell supernatants were harvested after 48 h. The expression
of all fusion proteins was comparable (Fig. 1 d), as assayed
by [
 
35
 
S]methionine labeling. Since mIL-10 has N-linked
oligosaccharides, whereas vIL-10 does not, the [
 
35
 
S]me-
thionine labeling was performed in the presence of tunica-
mycin to eliminate the glycosylation and size differences
between the various chimeric constructs. The COS cell su-
pernatants were then tested in the thymocyte coprolifera-
tion assay. This is a discordant response, since cIL-10 causes
proliferation and vIL-10 does not. The results in Fig. 1 c
unexpectedly showed that the difference in activity be-
tween mIL-10 and vIL-10 does not reside in the NH
 
2
 
-ter-
minal region of the molecule. Thus, the COOH-terminal
57 amino acids, or NH
 
2
 
-terminal 35 amino acids of mIL-10
could be replaced with the corresponding vIL-10 residues
without affecting the costimulation of thymocyte prolifera-
tion. Analysis of the proliferative data in Fig. 1 c suggested
that the positions responsible for the immunological differ-
ences between mIL-10 and vIL-10 reside in the central re-
gion of the peptides. Importantly, substitution of large por-
tions of mIL-10 with vIL-10 did not destroy biological
activity.
A review of the sequence data (Fig. 1 a) suggests that
amino acids 42 and 43 (encoding QL in both murine and
human, but EV in viral IL-10) and/or amino acids 87–89
(encoding IKA in human, IKE in murine, and AKD in vi-
ral IL-10) may be responsible for the functional differences.
Constructs of mIL-10 cDNA with amino acids Q42E,
L43V, I87A, and E89D were made (Fig. 1 b), and COS
cell supernatants were again tested in the thymocyte assay
(Fig. 1 c). The results clearly demonstrate that a single amino
acid change at position 87(I
 
®
 
A) of the mature peptide se-
quence rendered mIL-10 inactive in the assay, whereas
changes in amino acids 42, 43, or 89 had no effect on im-
munological activity. Thus, isoleucine 87 was critical for
the immunostimulatory function in this assay. cIL-10 and
vIL-10 are also discordant for their proliferative effects on
mast cells: cIL-10, but not vIL-10, is a potent stimulator of
mast cell proliferation, including the murine MC/9 mast cell
line (18, 24). To validate the thymocyte assay data and con-
clusions, we assayed the chimeric IL-10s in the MC/9 assay
and obtained an identical immunological profile (Fig. 1 e).
Given the close homology between murine and human
IL-10s, it was important to determine if the identical 
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changes could alter the activity of hIL-10. The appropriate
constructs were cloned and tested in the MC/9 prolifera-
tion assay (Fig. 2 a). The results again demonstrated that the
amino acid at position 87, but not at positions 42, 43, or
89, determined the biological properties of the cytokine,
and the myc-his–tagged protein had biological activities
comparable to wild-type hIL-10. Thus, a change in amino
acid residue 87 of hIL-10 rendered it inactive in the MC/9
assay. Similar results were obtained with hIL-10 constructs
in the murine thymocyte assay (not shown). Western blot-
ting of the supernatants (Fig. 2 b) showed equivalent
amounts of expressed protein, demonstrating again that the
single amino acid change had not artifactually altered pro-
tein translocation, stability, transport, or secretion.
To determine if the alanine to isoleucine substitution at
position 87 of vIL-10 was sufficient to allow it to acquire
proliferative activity, the vIL-10(A87I) mutation was made
and tested on MC/9 cells. The results show that although
vIL-10(A87I) was not as active as hIL-10 in this assay, the
single residue change significantly enhanced the prolifera-
tive capacity of vIL-10 (Fig. 2 c), demonstrating that isole-
ucine 87 was critical in determining the immunostimula-
tory activity of this cytokine. Although the protein content
of the COS cell supernatants was not quantitated for this
experiment, quantitative assays in Fig. 5 d show identical
results.
 
Isoleucine to Alanine Substitution Does Not Alter Immunosup-
pressive Activities.
 
Both hIL-10 and vIL-10 inhibit IFN-
 
g
Figure 1. (a) Alignment of amino acid sequences of hIL-
10, mIL-10 and vIL-10. Sequence and numbering based on
the mature peptide without the signal sequence. Amino
acid residues differing from hIL-10 are marked by boxes.
(b) Chimeric IL-10 constructs made by PCR based mu-
tagenesis. Constructs included exchange of large segments
of the molecules or single amino acid changes at positions
42, 43, 87, and 89. (c) Activity of IL-10 constructs for thy-
mocyte proliferation. Purified mIL-10/vIL-10 chimeric cDNA plasmids were transfected into COS-7 cells, supernatants were obtained after 48 h, and
various concentrations were added to 2 3 105 thymocytes along with IL-2 and IL-4 for 3 d. Proliferation was assessed by 18-h [3H]thymidine incorpora-
tion. (d) Expression of various IL-10 chimeric constructs after internal labeling with [35S]methionine. Supernatants were concentrated 10-fold and ana-
lyzed on a 14% SDS-PAGE gel. (e) Activity of IL-10 constructs for MC/9 proliferation resides at amino acid 87. Various concentrations of COS super-
natants were added to MC/9 cells for 24 h, and proliferation assessed by 6-h [3H]thymidine incorporation. 
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synthesis by activated human PBMCs (18). To determine if
the various constructs retained both biological and immu-
nosuppressive activity, human PBMCs were isolated and
stimulated with anti-CD3 mAb (OKT3) in the presence of
COS supernatants containing various IL-10 constructs. The
results in Fig. 3 a show that the various hIL-10 and vIL-10
constructs all suppressed IFN-
 
g
 
 production to a similar de-
gree. Thus, suppression is the dominant effect in this assay,
regardless of peptide structure. However, the constructs did
not inhibit the OKT3-driven proliferative response, dem-
onstrating that the peptides were not toxic to the cells (Fig.
3 b). mIL-10 constructs (which do not bind hIL-10R1 [36])
did not suppress IFN-
 
g
 
 production by human PBMCs (not
shown). Together, these results demonstrate that the con-
structs have retained biological activity, immunosuppres-
sive activity, and receptor species specificity.
It has been shown that cIL-10 can be immunosuppres-
sive or immunostimulatory in vivo, whereas vIL-10 is al-
most exclusively immunosuppressive (26, 27). Our previ-
ous report showed that rejection of mouse heart allografts
was substantially delayed when the grafts were induced to
express vIL-10, but not mIL-10 (27). To determine if the
various IL-10 constructs could suppress the alloantigen re-
sponse and prolong cardiac allograft survival, plasmid DNA
encoding several of the different constructs, under the con-
trol of the CMVie promoter (28), was transferred into mu-
rine cardiac allografts and the effects on graft survival were
determined. The results (Fig. 3, c and d) were consistent
with those of the in vitro assays and our previous publica-
tion (27). vIL-10, as well as cIL-10 constructs in which
amino acid 87 had been changed from isoleucine to ala-
nine, all prolonged graft survival, whereas hIL-10, mIL-10,
vIL-10(A87I), and hIL-10(A89D) did not prolong allograft
survival. These results confirm the finding that a reciprocal
 
exchange of a single amino acid can determine the spec-
trum of immunosuppressive or immunostimulatory activi-
ties of this cytokine. Presumably, the translation products
of the IL-10 constructs interacted in vivo with T cells, B
cells, APCs, and other cell types in this in vivo assay, and
graft survival represents the integrated response of these di-
verse cell types. The results reveal that immunosuppression
in vivo was associated with the alanine substitution, and
that isoleucine-associated immunostimulation was domi-
nant over the immunosuppressive activity of the peptide.
This stands in contrast to the results of the IFN-
 
g
 
 assay in
which all constructs are immunosuppressive. This likely re-
flects the more complex cellular interactions in vivo com-
pared with the in vitro assay.
 
Isoleucine to Alanine Substitution Does Not Alter Receptor
Binding Specificity and STAT Activation.
 
The activities of
IL-10 are mediated through a cell surface receptor complex
consisting of a ligand binding chain (IL-10R1) and a signal
transducing accessory chain (IL-10R2) (33, 39, 40). Al-
though IL-10R2 alone does not bind IL-10, only cells ex-
pressing both IL-10R1 and IL-10R2 can mediate IL-10
signal transduction (33). To determine if the single amino
acid change affected the receptor binding specificity of
IL-10, we stimulated 16-9 CHO cells with IL-10. These
cells had been stably transfected to express an HLA-B7 re-
porter gene along with hIL-10R2 alone; the hIL-10R1
chimeric receptor, in which the transmembrane and intra-
cellular domains of the hIFN-
 
g
 
R1 chain were substituted
for the transmembrane and intracellular domains of the
hIL-10R1 chain; or both receptors. We previously showed
that hIL-10 stimulates IFN-
 
g
 
–like responses only in those
cells that express both receptors, inducing both MHC class I
antigen expression and Stat1 activation (33). Fig. 4 a shows
that both hIL-10 and hIL-10(I87A) induced identical MHC
Figure 2. (a) Single mutation in amino acid 87 of hIL-10 prevents MC/9 prolifera-
tion. (b) Western blotting of hIL-10 constructs shows equivalent amounts of proteins in
COS-7 cell supernatants. (c) Single mutation in amino acid 87 of vIL-10 enhances MC/9
proliferation.218 IL-10 Immunostimulatory Domain
class I expression only in cells expressing both receptors,
demonstrating that both hIL-10 and hIL-10(I87A) require
IL-10R1 and IL-10R2 to mediate signal transduction, and
that the single amino acid change did not alter peptide re-
ceptor binding specificity. An EMSA was performed with
the same cells to determine STAT activation. The results
show the comparable formation of DNA-binding com-
plexes in both hIL-10– and hIL-10(I87A)–treated cells, and
these complexes were supershifted with anti-Stat1 but not
anti-Stat3 antibodies (Fig. 4 b). To explore if this result can
be extended to more physiological IL-10–responsive mu-
rine cells, the IL-3–dependent murine pro-B cell Ba/F3
line expressing mIL-10R1 was also used. This line prolifer-
ates in a concordant fashion to both cIL-10 and vIL-10
(29–31), and it was shown previously that Stat1, Stat3, and
Stat5 are activated upon cIL-10 treatment in Ba/F3-mIL-
10R1 cells (34). Fig. 4 c shows that both hIL-10 and hIL-
10(I87A) induced Stat1, Stat3, and Stat5 activation. These
results further demonstrate that the alanine substitution did
not alter the receptor binding specificity and Janus kinase
(JAK)-STAT signal transduction pathway activation in these
particular cell lines that respond in a concordant fashion to
cIL-10 and vIL-10.
The Single Amino Acid at Position 87 Determines Binding
Affinity to IL-10 Receptors. The hIL-10, hIL-10(I87A), vIL-
10, and vIL-10(A87I) peptides were expressed in E. coli as
described in Materials and Methods. The two-step purifica-
tion of various IL-10 constructs expressed in bacteria
yielded homogeneous proteins as judged by silver-stained
SDS-PAGE (Fig. 5 a). No biologically functional differ-
ences between wild-type hIL-10 produced in our labora-
tory and commercially obtained E. coli–expressed hIL-10
were detected in the different assays performed (data not
shown). A quantitative comparison of hIL-10, hIL-10(I87A),
vIL-10, and vIL-10(A87I) binding to Ba/F3-mIL-10R1
cells was obtained in competitive displacement experiments
(Fig. 5 b). Cells were incubated with a constant concentra-
tion of 125I-labeled hIL-10 in the presence of varying
amounts of unlabeled IL-10 constructs. hIL-10 was an ef-
fective competitor for 125I-labeled hIL-10 binding; the ef-
fective 50% inhibitory concentration value was z200 pM.
The single amino substitution at position 87(I®A) dramat-
ically reduced its receptor binding ability; the effective 50%
inhibitory concentration value for hIL-10(I87A) was at least
100-fold higher than for hIL-10, i.e., z20 nM. vIL-10 was a
very weak competitor for 125I-labeled hIL-10 binding;
however, the alanine to isoleucine substitution at position
87 dramatically enhanced its receptor binding ability, and the
effective 50% inhibitory concentration value for vIL-10(A87I)
was z6 nM, compared with at least 200 nM for vIL-10. This
suggests that other residues also contribute to differences in the
affinity of cIL-10 and vIL-10 for the receptor.
We compared the abilities of varying doses of hIL-10,
hIL-10(I87A), vIL-10, and vIL-10(A87I) to stimulate short-
term proliferation of Ba/F3-mIL-10R1 cells in order to
calculate specific activities (Fig. 5 c). hIL-10 induced prolif-
eration with a specific activity of 200 U/nM, and the single
substitution at position 87(I®A) reduced its activity only
z10-fold to 20 U/nM, despite being 100-fold less effective
in receptor binding. Unexpectedly, and in contrast, vIL-10
stimulated Ba/F3-mIL-10R1 cells with a specific activity
of 300 U/nM, which was higher than that of hIL-10, de-
Figure 3. (a) IL-10 inhibits IFN-g production
but not proliferation of PBMCs. PBMCs were pu-
rified from healthy donors, and 2 3 105 cells per
well were incubated with soluble OKT3 (0.1 mg/
ml) plus various concentrations of IL-10 COS su-
pernatants for 72 h. IFN g production was mea-
sured by two-antibody capture ELISA (left), and
proliferation was measured by 18-h [3H]thymidine
incorporation (right). (b) A single mutation in cIL-
10 allows prolongation of cardiac allograft survival.
Donor neonatal C57BL/6 mouse hearts were di-
rectly injected with 0.31 mg of various IL-10 plas-
mid DNA constructs along with 10 mg dendrimer
G5-EDA, and transplanted into CBA/J recipients.
Survival of cardiac allografts was followed with
EKG monitoring every other day. Only vIL-10,
hIL-10(I87A), and mIL-10(I87A) prolonged car-
diac allograft survival (P , 0.01 for each compared
with vector).219 Ding et al.
spite seriously impaired binding of vIL-10 compared with
hIL-10 to the IL-10 receptor. Furthermore, the single amino
acid substitution at position 87 of vIL-10 (A®I) slightly re-
duced the specific activity compared with wild-type vIL-10
(200 U/nM), despite enhanced receptor binding affinity. Al-
though some of the apparent differences in the specific activ-
ities of these peptides could be due to some impurities or
misfolding of our bacterial-derived products, the observation
remains that there is a significant dichotomy between affinity
and specific activity. Thus, biological responses and specific
activities did not strictly correlate with ligand affinity, a phe-
nomenon reported previously for this ligand (31), and com-
mensurate with the results in Fig. 4, b and c, in which STAT
activation was not quantitatively or qualitatively altered de-
spite changes in ligand structure and affinity.
We also compared the abilities of hIL-10, hIL-10(I87A),
vIL-10, and vIL-10(A87I) to stimulate short-term prolifer-
ation in the discordant MC/9 cell assay. Fig. 5 d shows that
the specific activity of hIL-10 on MC/9 cells was 20 U/nM,
and therefore 10-fold less active than observed for Ba/F3-
mIL-10R1 cells. Neither hIL-10(I87A) nor vIL-10 in-
duced MC/9 proliferation over the range of concentrations
tested. Thus, their low receptor affinity abrogated any spe-
cific activity in this cell line. The single amino acid substi-
tution at position 87 of vIL-10 (A®I) enabled it to induce
MC/9 proliferation. It had a specific activity of 3 U/nM,
and a reduced plateau compared with hIL-10, showing that
vIL-10(A87I) is a partial agonist for MC/9 cells. This cor-
relates with its reduced receptor affinity (Fig. 5 b). Thus, in
this discordant MC/9 assay (Fig. 5 d), specific activities
correlated well with relative affinities, whereas in the con-
cordant Ba/F3-mIL-10R1 assay (Fig. 5 c), specific activities
did not correlate with affinity.
Discussion
These results demonstrate that a single amino acid
change at position 87 of cIL-10, corresponding to the vIL-10
Figure 4. (a) Induction of MHC class I antigen expression by IL-
10. The 16-9 CHO cell lines expressing an HLA-B7 reporter con-
struct and hIL-10R1/hIFN-gR1 chimera and/or hIL-10R2 were
exposed to control or COS cell supernatants (10%) containing hIL-
10 or hIL-10(I87A) for 72 h and stained for HLA-B7. Open histo-
grams represent negative controls; shaded histograms represent
treated groups. (b) Induction of Stat1 activation by IL-10. The 16-9
cells expressing hIL-10R1/hIFN-gR1 chimera plus hIL-10R2 were
exposed to COS supernatants (100%) for 15 min, the cells were
lysed, and nuclear extracts were obtained for binding to 32P-labeled
22-bp IFN-g activation sequence (GAS) from human IFN-g regu-
latory factor 1 (hIRF-1). Only anti-Stat1 but not anti-Stat3 caused
supershifting of the complex. (c) Induction of Stat1, Stat3, and Stat5
activation by IL-10. Ba/F3-mIL-10R1 cells were exposed to COS
supernatants (100%) for 15 min, and the EMSAs were performed us-
ing a 32P-labeled 22-bp IFN-g response region (GRR) probe.220 IL-10 Immunostimulatory Domain
sequence, alters its receptor binding affinity and spectrum
of biological activities. Since all of the constructs retained
both immunostimulatory activity in Ba/F3-mIL-10R1
cells and immunosuppressive activity in the IFN-g assay,
the single amino acid mutations did not alter the stability of
the IL-10 molecules and destroy biological function. Since
reciprocal residue exchanges in cIL-10 and vIL-10 resulted
in predictable receptor binding activities and biological
responses, the results are unlikely to be an artifact of the
system. The preservation of species specificity and the re-
quirement for both receptor subunits for biological responses
show that specific receptor binding and activation by ligand
have been maintained. These results reveal separable func-
tions for IL-10, and a new, unexpected mechanism for the
regulation of IL-10 stimulatory and suppressive activities.
The selective modulation of vIL-10 receptor interactions
and subsequent functional spectrum by EBV may have
provided a useful strategy for the virus to skew host im-
mune responses and promote pathogenesis.
It is important to determine how this conservative amino
acid change affects both the structure and function of the
peptide. Structural comparisons show that the most signifi-
cant differences in the amino acid sequences of viral and
cellular IL-10 are found at the NH2 terminus (Fig. 1 a).
Likewise, the crystal structures of hIL-10 and vIL-10 dem-
onstrate six a-helices within each subunit of a homodimer
with close topological resemblance to IFN-g (35–38), and
a significant difference in the conformation of the NH2-
Figure 5. (a) Expression and purification of various
IL-10s. Silver-stained SDS-PAGE of purified recombi-
nant hIL-10, hIL-10(I87A), vIL-10, and vIL-10(A87I).
IL-10 is at 18 kD; maltose binding protein (MBP) is at
45 kD. (b) A quantitative comparison of various con-
structs binding to mIL-10R was obtained in competi-
tive displacement experiments. Ba/F3-mIL-10R1 cells
were incubated in 100 pM 125I–hIL-10 in the presence
of varying amounts of unlabeled IL-10 constructs. (c)
Specific activities of various IL-10 constructs on Ba/
F3-mIL-10R1 cell proliferation. (d) Specific activities
of various IL-10 constructs on MC/9 cell proliferation.221 Ding et al.
terminal coil of vIL-10 compared with hIL-10. The loop
between a-helices A and B also differs significantly be-
tween hIL-10 and vIL-10. These differences, which are in
the region of the greatest linear amino acid sequence diver-
gence between vIL-10 and hIL-10, could account for the
immunological differences between the molecules. Addi-
tional modeling comparisons to other members of the IFN
family predict that the A–B loop, A helix, B helix, D helix,
and F9 helix may interact with the receptor and be impor-
tant for biological responses (37, 39). Recently, Gesser et
al. (41) performed in vitro biological activity tests on non-
apeptides corresponding to the COOH and NH2 termini
of hIL-10. Their results suggested that the COOH-termi-
nal peptide possesses immunoinhibitory, whereas the NH2-
terminal peptide possesses immunostimulatory, activity (41).
However, the report did not show receptor binding, recep-
tor specificity, or the biological effects of reciprocal ex-
changes of amino acids. Furthermore, the homologies among
human, murine, and viral peptides in these regions do not
correlate with the difference between cIL-10 versus vIL-10
activities. Our present results do not confirm their findings
or the prediction of modeling studies (35–38). Instead, by
using mIL-10/vIL-10 hybrids, we showed that the central
region of cIL-10 is mainly responsible for its stimulatory
activity on both murine thymocytes and mast cells. Further
mutagenesis determined that the single amino acid isoleu-
cine at position 87 is critical for receptor binding and stim-
ulatory responses. Conversely, mutating vIL-10 from ala-
nine to isoleucine at the corresponding position can convert
vIL-10 to a partial agonist with immunostimulatory activi-
ties. Position 87 lies in the distal aspect of the loop between
helices C and D and is in a region of highly conserved ter-
tiary structure (37, 39). It was unexpected that a single,
conservative amino acid change could be responsible for
the majority of the immunostimulatory activity of the pep-
tide; and computer modeling also suggested this single
amino acid change in cIL-10 did not alter the structural
conformation (our unpublished data). Our present results
imply that amino acid at position 87 likely interacts with a
critical element of the IL-10 receptor complex, and IL-10
mutants change their biological responses by affecting their
receptor binding affinities.
The IL-10R complex consists of two chains. IL-10R1 is
a cell surface receptor with a single transmembrane domain
and is a member of the class II cytokine receptor family.
hIL-10R1 is species specific and does not bind mIL-10,
whereas mIL-10R1 binds both mIL-10 and hIL-10. Nei-
ther hIL-10R1 nor mIL-10R1 binds vIL-10 well. Previous
reports (31) and our present data show that vIL-10 bound
to IL-10R1 with at least 1,000-fold less affinity than hIL-10
(Fig. 5 b). Isoleucine to alanine substitution of hIL-10 re-
duced its binding affinity at least 100-fold, whereas alanine
to isoleucine substitution enhanced vIL-10 binding affinity
by at least 100-fold. Despite these differences in affinities,
the specific activities of hIL-10, hIL-10(I87A), vIL-10, and
vIL-10(A87I) were similar in the Ba/F3-mIL-10R1 cells
(Figs. 4 c and 5 c) and the CHO cells (Fig. 4 b). In contrast,
the specific activity of hIL-10 in MC/9 cells is 10-fold
lower than in Ba/F3-mIL-10R1 cells, hIL-10(I87A) and
vIL-10 do not have any discernible activity on this line,
and vIL-10(A87I) is a partial agonist for MC/9 cells. These
latter findings correlate well with receptor affinity. The is-
sue is to understand why significant differences in receptor
affinity do or do not correlate with the specific activity of
the various peptides in bioassays on particular cell lines.
The lack of strict correlation between affinity and specific
activity might be due to the amount of IL-10R expressed
on the cells, the ratio of IL-10R1 to IL-10R2 on a cell,
and/or the precise signal transduction mechanisms used by
a particular cell line. The data in Fig. 4 show that the single
mutation at position 87 of hIL-10 did not affect JAK-
STAT signaling in two different concordant cell lines (CHO
and Ba/F3). However, preliminary data (unpublished) sug-
gest that in discordant cell lines, JAK-STAT activation is
markedly sensitive to the position 87 amino acid. This
finding suggests that a membrane-proximal event integrates
ligand affinity and specific activity responses. The exact
structural basis for this unusual finding may also relate to
dynamic rather than equilibrium measurements of recep-
tor–ligand interactions. Thus, on and off rates or receptor
internalization may be more revealing than affinity. It is
possible that other ligands for the IL-10R complex not yet
discovered could account for some of our observations.
Likewise, there could also be other receptor chains that re-
main undescribed at this time. However, there are con-
straints on these speculative possibilities. Thus, while IL-
10R2 alone does not bind IL-10, it is a critical component
of the receptor complex since only cells expressing both
IL-10R1 and IL-10R2 can mediate IL-10 signal transduc-
tion (33; and Fig. 4 a). CRF2-4 (IL-10R2) knockout mice
have characteristics similar to IL-10 knockout mice and
develop chronic colitis (40), suggesting that IL-10R2 is es-
sential for IL-10–mediated immunosuppressive effects, that
IL-10R1 does not function on its own, and that possible al-
ternative R2 chains do not mediate immunosuppression.
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